Abbott Laboratories (ABT) Accounts Payables (2009 - 2026)

Abbott Laboratories has disclosed Accounts Payables across 18 years of filings, most recently posting $4.7 billion for Q1 2026.

• Accounts Payables for Q1 2026 came in at $4.7 billion, up 11.03% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.7 billion (up 11.03% YoY), and the FY2025 annual result was $4.2 billion, up 1.07% from the prior year.
• Accounts Payables came in at $4.7 billion for Q1 2026 at Abbott Laboratories, up from $4.2 billion in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $4.8 billion in Q1 2022 to a low of $4.0 billion in Q3 2023.
• The 5-year median for Accounts Payables is $4.2 billion (2023), against an average of $4.3 billion.
• Across the five-year window, Accounts Payables rose 16.99% in 2022 and retreated 12.4% in 2023, its largest moves.
• Abbott Laboratories' Accounts Payables stood at $4.6 billion in 2022, then slipped by 6.77% to $4.3 billion in 2023, then decreased by 2.33% to $4.2 billion in 2024, then climbed by 1.07% to $4.2 billion in 2025, then increased by 10.35% to $4.7 billion in 2026.
• The last three Accounts Payables figures came in at $4.7 billion (Q1 2026), $4.2 billion (Q4 2025), and $4.1 billion (Q3 2025), per Business Quant data.